SCHEMBL17277995

SCHEMBL17277995

COc1cc(-c2cc(OC)cc(C(C)(C)C)c2OP(Oc2ccc(C)cc2C)Oc2ccc(C)cc2C)c(OC(=O)OC(C)(C)C)c(C(C)(C)C)c1

nearest known ligand 0.36

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.36
CISD2 Q8N5K1 1/20 0.32
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
GAA P10253 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
ELANE P08246 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17280435 0.90 ELANE (0.30) L3MBTL1ELANE
SCHEMBL17364572 0.88 ALDH1A1 (0.30)
SCHEMBL18828155 0.87 CA1 (0.36) L3MBTL1CA1CA2GAA
SCHEMBL30252476 0.87 CA1 (0.36) L3MBTL1CA1CA2GAA
SCHEMBL17280437 0.85 ALDH1A1 (0.36) GAAELANE
SCHEMBL17277942 0.85 APEX1 (0.34) CA1CA2GAAELANE
SCHEMBL17280444 0.85
SCHEMBL17280436 0.83 MEN1 (0.32) ELANE
SCHEMBL18682925 0.83 TNFRSF1A (0.34) CA1CA2ELANE
SCHEMBL17280447 0.81 ALDH1A1 (0.36) GAAELANE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9840524-B2 Process for reducing the chlorine content of organomonophosphites using two solutions EVONIK DEGUSSA GMBH (DE) 2017-12-12 US disclosed
US-9840524-B2 Process for reducing the chlorine content of organomonophosphites using two solutions EVONIK DEGUSSA GMBH (DE) 2017-12-12 US disclosed
US-9751904-B2 Method for reducing the chlorine content of organomonophosphites using dimethylaminobutane, triethylamine or triethanolamine EVONIK DEGUSSA GMBH (DE) 2017-09-05 US disclosed
US-20170121355-A1 PROCESS FOR REDUCING THE CHLORINE CONTENT OF ORGANOMONOPHOSPHITES USING TWO SOLUTIONS EVONIK DEGUSSA GMBH (DE) 2017-05-04 US disclosed
US-20170121355-A1 PROCESS FOR REDUCING THE CHLORINE CONTENT OF ORGANOMONOPHOSPHITES USING TWO SOLUTIONS EVONIK DEGUSSA GMBH (DE) 2017-05-04 US disclosed
US-20170088570-A1 METHOD FOR REDUCING THE CHLORINE CONTENT OF ORGANOMONOPHOSPHITES USING DIMETHYLAMINOBUTANE, TRIETHYLAMINE OR TRIETHANOLAMINE EVONIK DEGUSSA GMBH (DE) 2017-03-30 US disclosed
EP-2947089-B1 NOVEL MONOPHOSPHITE LIGANDS WITH A CARBONATE GROUP EVONIK DEGUSSA GMBH (DE) 2016-08-24 EP disclosed
EP-2947090-B1 NOVEL MONOPHOSPHITE LIGANDS WITH A TERTIARY BUTYLOXYCARBONYL GROUP EVONIK DEGUSSA GMBH (DE) 2016-08-24 EP disclosed
US-9221850-B2 Monophosphite ligands having a tert-butyloxycarbonyl group EVONIK INDUSTRIES AG (DE) 2015-12-29 US disclosed
US-9212195-B1 Monophosphite ligands having a carbonate group EVONIK INDUSTRIES AG (DE) 2015-12-15 US disclosed
US-20150336988-A1 NOVEL MONOPHOSPHITE LIGANDS HAVING A TERT-BUTYLOXYCARBONYL GROUP EVONIK INDUSTRIES AG (DE) 2015-11-26 US disclosed
WO-2015176929-A1 METHOD FOR REDUCING THE CHLORINE CONTENT OF ORGANOMONOPHOSPHITES USING DIMETHYLAMINOBUTANE, TRIETHYLAMINE OR TRIETHANOLAMINE EVONIK DEGUSSA GMBH (DE) 2015-11-26 WO disclosed
WO-2015176927-A1 METHOD FOR REDUCING THE CHLORINE CONTENT OF ORGANOMONOPHOSPHITES USING TWO SOLUTIONS EVONIK DEGUSSA GMBH (DE) 2015-11-26 WO disclosed
EP-2947090-A1 NOVEL MONOPHOSPHITE LIGANDS WITH A TERTIARY BUTYLOXYCARBONYL GROUP Evonik Industries AG (DE) 2015-11-25 EP disclosed
EP-2947089-A1 NOVEL MONOPHOSPHITE LIGANDS WITH A CARBONATE GROUP Evonik Degussa GmbH (DE) 2015-11-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170121355-A1 PROCESS FOR REDUCING THE CHLORINE CONTENT OF ORGANOMONOPHOSPHITES USING TWO SOLUTIONS PHOSPHO1, PLCG2, PLCG1 L3MBTL1 2733/4885CISD2 104/4885CA1 514/4885
US-20150336988-A1 NOVEL MONOPHOSPHITE LIGANDS HAVING A TERT-BUTYLOXYCARBONYL GROUP TERF2, NUDT1, TERF2IP L3MBTL1 681/4885CISD2 3285/4885CA1 4792/4885
US-20170088570-A1 METHOD FOR REDUCING THE CHLORINE CONTENT OF ORGANOMONOPHOSPHITES USING DIMETHYLAMINOBUTANE, TRIETHYLAMINE OR TRIETHANOLAMINE PHOSPHO1, SGMS2, SGMS1 L3MBTL1 850/4885CISD2 161/4885CA1 594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.